The determinants of cost-effectiveness potential: An historical perspective on lipid-lowering therapies

PharmacoEconomics

Volumn 31, Issue 5, 2013, Pages 445-454

  Refoios Camejo, Rodrigo ^a   McGrath, Clare ^b   Miraldo, Marisa ^c   Rutten, Frans ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONCEPTUAL FRAMEWORK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROMOTION; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LOW RISK POPULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG DESIGN; GREAT BRITAIN; HUMANS; HYPOLIPIDEMIC AGENTS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 84877941189     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0041-x     Document Type: Article

References (41)

1. Attridge J. Innovation models in the biopharmaceuticals sector: innovation in Life Sciences Initiative. London: Imperial College London; 2006.
2. Abbott T, Vernon J. The cost of pharmaceutical price reductions: a financial simulation model of R&D decisions [NBER Working Series no. 11114]. Cambridge: NBER; 2005.
3. Bardey D, Bommier A, Jullien B. Retail price regulation and innovation: reference pricing in the pharmaceutical industry. J Health Econ. 2010;29(2):303-16.
4. Barton J, Emanuel E. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA. 2005;294(16):2075-83.
5. Boersma C, Broere A, Postma M. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health. 2010;13(6):853-6.
6. CBO. Research and development in the pharmaceutical industry. Washington: The Congress of the United States - Congressional Budget Office 2006.
7. Claxton K. OFT, VBP: QED? Health Econ. 2007;16:545-58.
8. Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Sculpher M, et al. Value-based pricing for NHS drugs: an opportunity not to be missed? British Med J. 2007;336:251-4.
9. Giacotto C, Santerre R, Vernon J. Drug prices and research and development investment behavior in the pharmaceutical industry. J Law Econ. 2005;48:195-214.
10. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics. 2008;26(7):589-602.
11. Hoyle M. Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics. 2011;29(1):1-15.
12. Jena A, Philipson T. Cost-effectiveness as a price control. Health Aff. 2007;26(3):696-703.
13. Jena A, Philipson T. Cost effectiveness analysis and innovation. J Health Econ. 2008;27(5):1224-36.
14. Kanavos P, Manning J, Taylor D, Schurer W, Checchi K. Implementing value-based price for pharmaceuticals in the UK. London: 2020health.org; 2010.
15. Kettle T, Moen J, Griliches Z. Do subsidies to commercial R&D reduce market failures? Microeconometric evaluation studies. Res Policy. 2000;29:471-95.
16. Lichtenberg F. Probing the link between gross profitability and R&D spending. Health Aff. 2001;20:221-2.
17. Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. Geneva: WHO; 2010.
18. Pekarsky B. Should financial incentives be used to differentially reward 'me-too' and innovative drugs? Pharmacoeconomics. 2010;28(1):1-17.
19. Refoios Camejo R, McGrath C, Herings R. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. Health Policy. 2011;100(1):18-24.
20. Refoios Camejo R, McGrath C, Herings R, Meerding W-J, Rutten F. Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectiveness. Value Health. 2012;15(2):381-8.
21. Refoios Camejo R, McGrath C, Rutten F. An empirical model of drug pricing and competition: a retrospective outlook of the pricing of lipid-lowering drugs. Int J Econ Bus Res. 2013;6 (in press).
22. Refoios Camejo R, McGrath C, Herings R, Starkie H, Rutten F. Assessing the determinants of the potential for cost effectiveness over time: the empirical case of COPD. Value Health. 2013;16(2):426-33.
23. Scherer F. The link between gross profitability and pharmaceutical R&D spending. Health Aff. 2001;20:216-20.
24. Sloan F, Hsieh C-R. The effects of incentives on pharmaceutical innovation. In: Sloan F, Kasper H, editors. Incentives and choice in health care. Cambridge: MIT Press; 2008.
25. Vernon J. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 2004;14(1):1-16.
26. Vernon J, Hughen W, Johnson S. Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/no-go decisions. Health Care Manag Sci. 2005;8:167-79.
27. The Health and Social Care Information Centre. PCA prescription cost analysis data 1980-2010. London: Department of Health; 2011. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions. Accessed 4 Mar 2013.
28. Joint Formulary Committee. British National Formulary 61. London: British Medical Association and Royal Pharmaceutical Society; 2011.
29. European Society of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil. 2007;14(2):S1-113.
30. Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
31. National Institute for Health and Clinical Excellence. NICE menu of Indicators. NICE: London; 2011 (updated 14 Sep 2012). http://www.nice.org.uk/ aboutnice/qof/indicators.jsp. Accessed 13 Oct 2012.
32. Office for National Statistics. All items retail price index (RPI) percentage change over 12 months: Table RP04. Newport: Office for National Statistics; 2010.
33. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
34. D'Agostino R, Russel M, Huse D, Ellison R, Silbershatz H, Wilson P, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272-81.
35. Erhardt L, Gotto G Jr. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis. 2006;185(1):12-20.
36. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events (technology appraisal 94). London: NICE; 2006.
37. National Collaborating Centre for Primary Care. Lipid modification - cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [clinical guideline 67]. London: NICE; 2008.
38. European Pharmaceutical Market Research Association. EphMRA anatomical classification guidelines 2009. EphMRA: Basel; 2009.
39. The Medicines and Healthcare products Regulatory Agency. Clinical practice research datalink. London: MHRA. http://www.cprd.com/. Accessed 3 Mar 2013.
40. The Health and Social Care Information Centre. Hospital episode statistics for England: inpatient statistics. Leeds: The Health and Social Care Information Centre; 2011. http://www.hesonline.nhs.uk. Accessed 3 Mar 2013.
41. National Institute for Health and Clinical Excellence. Prevention of cardiovascular disease at the population level (PH25). London: NICE; 2010. http://www.nice.org.uk/ph25. Accessed 3 Mar 2013.